Breast cancer prognosis associated with oncometabolite accumulation

The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National Cancer Institute discovered an association between the oncometabolite 2-hydroxyglutarate (2-HG) levels, DNA methylation patterns, and breast cancer prognosis.

The authors identified a breast cancer subtype with high levels of 2-HG, and a district DNA methylation pattern that was associated with reduced survival.

This breast cancer subtype was common in African-American breast cancer patients, who as a group have a high prevalence of aggressive breast cancers.

This study indicates that evaluation of 2-HG along with DNA methylation may be a useful biomarker for diagnosis and prognosis

More information: MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis, J Clin Invest. DOI: 10.1172/JCI71180

add to favorites email to friend print save as pdf

Related Stories

Linking risk factors and disease origins in breast cancer

Nov 20, 2013

Researchers from the Geisel School of Medicine at Dartmouth have found that epigenetic changes to DNA are associated with aging in disease-free breast tissues and are further altered in breast tumors. Epigenetic changes describe ...

DNA methylation level is marker of breast cancer risk

May 11, 2012

(HealthDay) -- Women with high levels of white blood cell (WBC) DNA methylation at the ATM loci have a significantly increased risk of breast cancer, regardless of family history or menopausal status, according ...

Recommended for you

ACG: Recent increase in incidence of young-onset CRC

12 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments